BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors

Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40–50% of cases are positive. To uncover other potential targetable mutations, we performed whole-genome sequencing of a highly aggressive BRAF (V600) and KIT (W557, V559,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Dahlman, Kimberly Brown, Xia, Junfeng, Hutchinson, Katherine, Ng, Charles, Hucks, Donald, Jia, Peilin, Atefi, Mohammad, Su, Zengliu, Branch, Suzanne, Lyle, Pamela L., Hicks, Donna J., Bozon, Viviana, Glaspy, John A., Rosen, Neal, Solit, David B., Netterville, James L., Vnencak-Jones, Cindy L., Sosman, Jeffrey A., Ribas, Antoni, Zhao, Zhongming, Pao, William
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2012
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3449158/
https://ncbi.nlm.nih.gov/pubmed/22798288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0097
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk